Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Ingo Mellinghoff

Department Chair

Memorial Sloan Kettering Cancer Center

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Cell Biology Cell Biology professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (12)

Mustafa Khasraw

Professor

Duke University

UNITED STATES

View details

Jennifer Clarke

Professor

University of California, San Francisco

UNITED STATES

View details

Maria Vieito

Clinical Investigator

Vall d'Hebron Institute of Oncology

SPAIN

View details

Timothy Cloughesy

Director of NeuroOncology Program/Professor

Ronald Reagan UCLA Medical Center

UNITED STATES

View details

Pim French

Full professor

Erasmus MC

NETHERLANDS

View details

Nelson Moss

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Quinn Ostrom

Assistant Professor

Duke University School of Medicine

UNITED STATES

View details

Luca Pasquini

Assistant Professor

Yale University

UNITED STATES

View details

Matthias Karajannis

Professor of Pediatrics

Weill Cornell Medical College

UNITED STATES

View details

Kristoffer Rohrberg

Ass. Professor

Faculty of Health and Medical Sciences, University of Copenhagen

DENMARK

View details

Susan Short

University of Leeds

UNITED KINGDOM

View details

Michael Platten

Heidelberg University

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ingo Mellinghoff

Research Interests

Make your next move.

Explore related searches

Articles (20)

Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas

A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): Updated efficacy and safety.

Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from the phase 3 INDIGO study.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors (vol 44, pg 1, 2026)

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial (APR, 10.1200/JCO-25-01137, 2026)

Genomic landscape and evolutionary dynamics of <i>RAS</i> alterations in glioma: A large-scale clinicopathologic analysis

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma

Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment

Primitive neuronal component is a frequent finding among IDH-mutant astrocytomas with <i>RB1</i> alterations

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma

JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB

<SUP>18</SUP>F-BMS-986229 PET imaging of tumor PD-L1 expression in glioblastoma patients

Aberrant Somatic Hypermutation Plays Minor Role in the Evolution of Molecular Alterations at Recurrence in PCNSL

DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES

EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL

Glioblastoma distant recurrences preferentially occur along white matter tracts mapped using probabilistic diffusion tractography

IBRUTINIB IN COMBINATION WITH RITUXIMAB, METHOTREXATE (MTX), VINCRISTINE, AND PROCARBAZINE (R-MPV/I) FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (PCNSL)

Collaborators (12)

Mustafa Khasraw

Jennifer Clarke

Maria Vieito

Timothy Cloughesy

Pim French

Nelson Moss

Quinn Ostrom

Luca Pasquini

Matthias Karajannis

Kristoffer Rohrberg

Susan Short

Michael Platten

Make your next move.